Evidence map›Paper›PMID 15284859›Full record

ArticleLeukemia2004

Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas.

C Kelaidi, F Rollot, S Park, M Tulliez, B Christoforov, Y Calmus, P Podevin, D Bouscary, P Sogni, P Blanche and 1 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Leukemia, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Extrahepatic manifestations of chronic hepatitis C virus infection.Therapeutic advances in infectious disease · 2016
    Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. HCV and lymphoproliferation.Clinical & developmental immunology · 2012
    Review
  18. Review
  19. Hepatitis C virus infection and lymphoma.Mediterranean journal of hematology and infectious diseases · 2010
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

C Kelaidi1Department of Hematology, Hôpital Cochin, Université Paris V, Assistance Publique Hôpitaux de Paris, Paris, France.
F Rollot
S Park
M Tulliez
B Christoforov
Y Calmus
P Podevin
D Bouscary
P Sogni
P Blanche
F Dreyfus

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A link between chronic hepatitis C virus (HCV) infection and low-grade B-cell lymphomas has been suggested by epidemiological studies. Marginal zone lymphomas (MZLs) including splenic lymphomas with villous lymphocytes are among the most frequently reported subgroups in the setting of chronic HCV infection. In this study, we examined the effect of antiviral treatment in eight patients with HCV-associated MZL. We found that five out of eight patients have responded to interferon alpha and ribavirin. In some cases, hematologic responses were correlated to virologic responses. In addition, we report a case of large granular lymphocyte leukemia occurring in association with MZL and HCV, and responding to interferon and ribavirin. We suggest that there is an etiologic link between HCV and antigen-driven lymphoproliferative disorders.

Indexed as

AdultAgedAntiviral AgentsDrug Therapy, CombinationFemaleHepacivirusHepatitis CHumansInterferon-alphaLymphoma, B-CellMaleMiddle AgedProspective StudiesRetrospective StudiesRibavirinTreatment OutcomeAntiviral AgentsInterferon-alphaRibavirin

Identifiers

PMID15284859

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.